Elevance Health, Inc. Website

Elevance Health, Inc.

NYSE-ELV

Company Overview

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

  • Name

    Elevance Health, Inc.

  • CEO

    —

  • Website

    www.elevancehealth.com

  • Sector

    Health Care Providers and Services

  • Year Founded

    2001

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Elevance continues to use its scale-related advantages for the benefit of clients, and we remain intrigued by its ongoing efforts to align incentives with caregivers, including the deployment of high performance provider networks.

  • The company's Carelon services platform, which includes its PBM, should support material savings for clients, higher profitability for Elevance, and overall growth with cross-selling opportunities.

  • Management aims for relatively high annualized earnings growth of at least 12% in the long run.

Bears Say

  • The insurance and PBM industries will likely remain targets of regulators aiming to reduce the healthcare cost burden on society, which is its key ESG risk, in our opinion.

  • A mismatch in rates and medical utilization is constraining profits in throughout the MCO industry, which has weakened Elevance's near-term outlook.

  • The bulk of insurance membership growth in the long run may stem from lower-margin government-sponsored plans, creating a structural headwind to insurer profitability.

Source: Morningstar Analysis - Nov 12, 2025

What's happening

Nov 29, 2025 - Dec 30, 2025

Elevance Health Inc: Strong Monthly Performance Amidst Analyst Downgrades and Legislative Challenges

  • Elevance Health reported a 12% year-over-year revenue increase in its quarterly earnings.
  • The appointment of Amy Schulman as an independent director is expected to enhance governance and strategic direction.
  • Despite bearish pressures from analyst downgrades, the stock outperformed both the S&P 500 and the Health Care sector.

Over the past month, Elevance Health Inc (ELV) experienced a notable overall movement of 6.0%, significantly outperforming the S&P 500's return of 1.5%. This performance reflects strong interest in ELV despite bearish pressures stemming from recent analyst downgrades and legislative developments affecting the healthcare sector. On December 18, Morgan Stanley revised its price target for ELV to $352 from $359 while maintaining an Equalweight rating, coinciding with concerns raised by a Republican healthcare bill that did not extend enhanced ACA subsidies.

The following day saw Deutsche Bank downgrade ELV to a "hold" rating with a price target set at $320, indicating caution among investors regarding future performance due to these legislative uncertainties. However, earlier in December brought positive indicators that contributed to ELV’s robust monthly performance; on December 15, Elevance reported impressive quarterly earnings with revenue increasing by 12% year-over-year. Analysts responded favorably as Robert W. Baird raised its price target significantly from $297 to $340 while maintaining a neutral stance on the stock.

Additionally, twelve analysts rated it as Buy and eleven as Hold during this period, showcasing confidence among market participants despite prevailing challenges. A key highlight was Amy Schulman's appointment as an independent director effective January 2026; her extensive experience is anticipated to enhance governance and strategic direction for Elevance Health moving forward.

Overall, while significant bearish influences impacted investor sentiment throughout December due to downgrades and legislative uncertainties surrounding ACA subsidies, bullish factors such as strong earnings reports helped sustain elevated interest in ELV’s stock performance during this timeframe. Ultimately, Elevance Health Inc outperformed both the broader S&P 500 index by an overperformance of 4.6% relative to it and surpassed the Health Care (XLV) sector by 7.8%.

NYSE:ELV